Abstract 3690
Background
With the success of immunotherapy in various solid cancers, the expression of programmed death-ligand 1 (PD-L1) in cancer cells has been attracting attention. The aim of this study was to analyze PD-L1 expression in resected UPS and evaluate its clinical impact.
Methods
All consecutive patients who were treated with UPS in Asan Medical Center, between January 1995 and December 2016, were retrospectively reviewed. PD-L1 staining was performed using SP263 antibody on their archived tissues. PD-L1 H-score was calculated by intensity (0-3) multiplied by proportion (0-100).
Results
A total of 176 patients with localized UPS who underwent curative-intent surgical resection were included in this study. There were 104 males (59.1%) and 72 females (40.9%), and the median age of patients was 59 years at the time of diagnosis. The most frequently involved primary site was extremities (84/176, 47.7%), followed by abdomen and pelvis (46/176, 26.1%), thorax (29/176, 16.5%), and head and neck (17/176, 9.7%). The PD-L1 analysis was available on slides from 114 (64.8%) patients and PD-L1 expression was observed in 83 (72.8%) cases. Intensity of staining varied between weak (44/83, 53.0%), intermediate (29/83, 34.9%), strong (10/83, 12.0%). Distribution of PD-L1 expression using different cut-off values were as follows: ≥1%: 83/114 (72.8%); ≥5%: 79/114 (69.3%); ≥10%: 52/114 (45.6%); ≥50%: 20/114 (17.5%). The 5-year disease free survival (DFS) rate seemed to be better in patients with PD-L1 positive than in patients with PD-L1 negative (56.5% vs 41.9%), but no statistical significant was observed (p = 0.183). There was a trend for better 5-year DFS rate with higher proportion of PD-L1 or higher PD-L1 H-score (proportion: 0% vs 1-49% vs ≥ 50, 41.9% vs 52.9% vs 70.1%, p = 0.098; H-score: 0 vs 1-100 vs ≥ 101, 41.9% vs 53.1% vs 75.7%, p = 0.087) without statistical singnificance.
Conclusions
In this study, PD-L1 protein expression was seen in substantial cases of resected UPS and it appeared to be a positive prognostic biomarker for longer DFS, although not statistically demonstrated. Further studies are needed comprehensively understand the impact of immune repertoire in UPS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
6079 - Invasive fungal diseases in patients with Hodgkin’s lymphoma before and after allogeneic hematopoietic stem cell transplantation
Presenter: Marina Popova
Session: Poster Display session 1
Resources:
Abstract
5995 - Invasive fungal diseases caused by rare pathogens in patients after hematopoietic stem cell transplantation (HSCT) & chemotherapy
Presenter: Yuliya Rogacheva
Session: Poster Display session 1
Resources:
Abstract
2961 - Safety and pharmacokinetics of novel CXCR4 antagonist YF-H-2015005 in the mobilization of hematopoietic stem cells in patients with non-Hodgkin's lymphoma
Presenter: Weiping Liu
Session: Poster Display session 1
Resources:
Abstract
5771 - Chemotherapy associated Hyponatremia in Hematological Malignancies: A retrospective study of 189 patients treated in a single medical center
Presenter: Vadim Lesan
Session: Poster Display session 1
Resources:
Abstract
1165 - Risk factors for Bacteremia-Associated Mortality of Aeromona sobria in Hematologic Malignancies
Presenter: Gabriel De la Cruz-Kú
Session: Poster Display session 1
Resources:
Abstract
5287 - Use of droplet digital polymerase chain reaction for detecting minimal residual disease: a prospective, multi-institutional study
Presenter: Hyunkyung Park
Session: Poster Display session 1
Resources:
Abstract
1886 - RUBIH2 — Use of NGS in haematological malignancies: from real world data to national recommendations, an innovative program to evaluate the impact of healthcare technology on patient care
Presenter: Severine Coquerelle
Session: Poster Display session 1
Resources:
Abstract
1940 - Outcomes of chronic myeloid leukemia with T315I mutation in the absence of targeted therapy or hematopoietic stem cell transplantation
Presenter: Nageswara Palukuri
Session: Poster Display session 1
Resources:
Abstract
1946 - Is bone marrow examination indispensible in chronic myeloid Leukemia at diagnosis ?
Presenter: Nageswara Palukuri
Session: Poster Display session 1
Resources:
Abstract
1904 - Incidence of Imatinib Resistance in Chronic Myeloid Leukemia (CML) Patients: Experience from Resource Poor Centre of Eastern India
Presenter: Debmalya Bhattacharyya
Session: Poster Display session 1
Resources:
Abstract